Company intelligence / Profile preview
2-BBB Medicines
Leiden, South Holland Province, Netherlands2-bbb.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
The company’s lead product, 2B3‑101, is in Phase I/IIa trials for primary brain tumors and brain metastases. Other programs are in early clinical or preclinical development for multiple sclerosis and retinal degeneration. The G‑Technology® platform has demonstrated the ability to enhance drug delivery across the blood-brain barrier with a favorable safety profile.
- Therapeutic areas
- OncologyOphthalmologyNeurology
- Modalities
- Liposomal drug formulationsSmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Three undisclosed pharma partnerships
Beyond the preview
Go deeper on 2-BBB Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-BBB Medicines.